Pulmonary Hypertension

Management of Complex Cardiovascular Problems: The Evidence-based Medicine Approach

Volumn , Issue , 2007, Pages 191-217

  McGoon, Michael D ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

Diagnosis; Genetics; Pulmonary hypertension; Treprostinil; Warfarin

Indexed keywords

EID: 84889351084     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470750858.ch7     Document Type: Chapter

References (68)

1. Barst RJ, McGoon MD, Torbicki A et al. Diagnosis and differential assessment of pulmonary arterial hypertension. Journal of American College of Cardiology 2004;43:40S-47S.
2. Yuan JXJ, Rubin LJ. Pathogenesis of pulmonary arterial hypertension. The need for multiple hits. Circulation 2005;111:534-538.
3. Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study. Lancet 2001;358(9288):1119-1123.
4. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. NEJM 1993;328:1732-1739.
5. Rich S, Dantzker DR, Ayres SM et al. Primary pulmonary hypertension: A national prospective study. Ann Int Med 1987;107:216-223.
6. Tuder RM, Groves BM, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present n plexiform lesions of pulmonary hypertension. Am J Path 1994;144:275-285.
7. Lane KB, Machado RD, Pauciulo MW et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium.[see comment]. Nature Genetics 2000;26:81-84.
8. Deng Z, Morse JH, Slager SL et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. American Journal of Human Genetics 67:electronically published, 2000.
9. Tapson VF, Gomberg-Maitland M, Mclaughlin V et al. Safety and Efficacy of Intravenous Treprostinil for Pulmonary Arterial Hypertension: A Prospective, Multicenter, Open-Label 12-Week Trial. Chest 2006;In press.
10. Gomberg-Maitland M, Tapson VF, Benza RL et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine 2005;172(12):1586-1589.
11. Newman JH, Trembath RC, Morse JA et al. Genetic basis of pulmonary arterial hypertension: current understanding and future directions. Journal of the American College of Cardiology 2004;43:33S-39S.
12. Loyd JE, Butler MG, Foroud TM, Conneally PM, Phillips JA, Newman JH. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine 1995;152:93-97.
13. Galie N, Badesch DB, Oudiz R et al. Ambrisentan therapy for pulmonary arterial hypertension. Journal of American College of Cardiology 2005;46(3):529-535.
14. Harrison R, Flanagan JA, Sankelo M et al. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. Journal of Medical Genetics 2003;40:865-71.
15. Marcos E, Fadel E, Sanchez O et al. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension.[see comment]. Circulation Research 2004;94:1263-1270.
16. Christman BW, McPherson CD, Newman JH et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. NEJM 1992;327:70-75.
17. Cacoub P, Dorent R, Maistre G et al. Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome. American J Cardiol 1993;71:448-450.
18. Altman R, Scazziota A, Rouvier J et al. Coagulation and fibrinolytic parameters in patients with pulmonary hypertension. Clinical Cardiology 1996;19:549-554.
19. Aguilar RV, Farber HW: Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. American Journal of Respiratory & Critical Care Medicine 162:1846-50, 2000.
20. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Annals of Internal Medicine 132:425-34, 2000.
21. Barst R, D. L, Badesch D, Frost A, Clinton L, Shapiro S, Naeije R, Simmoneau G, Galie N: Sitaxsentan Therapy for Pulmonary Arterial Hypertension. Journal of American College of Cardiology In Press, 2006.
22. Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, McLaughlin VV, Hill N, Tapson VF, Robbins IM, Zwicke D, Duncan B, Dixon RA, Frumkin LR: Sitaxsentan therapy for pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine 169:441-447, 2004.
23. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jobsis MM, Blackburn Jr. SD, Shortino D, Crow JW: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. New England Journal of Medicine 334:296-301, 1996.
24. Bonderman D, Fleischmann D, Prokop M, Klepetko W, Lang IM: Left main coronary artery compression by the pulmonary trunk in pulmonary hypertension. Circulation 105:265, 2002.
25. Channick RN, Rubin LJ, Simonneau G, Robbins IM, Tapson VF, Frost A, Badesch DB, Bodin F, Roux S: Bosentan, a dual endothelin receptor antagonist, improves exercise capacity and hemodynamics in patients with pulmonary arterial hypertension:results of a double blind, randomized, placebo-controlled trial [abstr]. Circulation 102 (Suppl II):II-100, 2000.
26. Currie PJ, Seward JB, Chan KL: Continuous wave Doppler determination of right ventricular pressure: A simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol 6:750-6, 1985.
27. D' Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT: Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Annals of Internal Medicine 115: 343-349, 1991.
28. Decuypere V, Delcroix M, Budts W: Left main coronary artery and right pulmonary vein compression by a large pulmonary artery aneurysm. Heart 90, 2004.
29. Demoncheauxa EAG, Higenbottamc TW, Kielyb DG, Wonga JM, Whartona S, Varcoea R, Siddonsa T, Spiveyd AC, Halle K, Gizee AP: Decreased whole body endogenous nitric oxide production in patients with primary pulmonary hypertension. Journal of Vascular Research 42:133-136, 2005.
30. Dorfmuller P, Perros F, Balabanian K, Humbert M: Inflammation in pulmonary arterial hypertension. European Respiratory Journal 22:358-63, 2003.
31. Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F, Simonneau G, Dartevelle P, Hamon M, Adnot S: Hyperplasia of pulmonary artery smooth muscle cells is causally related to overexpression of the serotonin transporter in primary pulmonary hypertension. Chest 121:97S-98S, 2002.
32. Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, Capron F, Simonneau G, Dartevelle P, Hamon M, Adnot S: Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. Journal of Clinical Investigation 108:1141-50, 2001.
33. Fuster V, Frye RL, Gersh BJ, McGoon MD, Steele PM: Primary pulmonary hypertension:natural history and the importance of thrombosis. Circulation 70:580-7, 1984.
34. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simmoneau G: Sildenafil citrate therapy for pulmonary arterial hypertension. New England Journal of Medicine 353:2148-57, 2005.
35. Giaid A, Saleh D: Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. New England Journal of Medicine 333:214-21, 1995.
36. Hassell KL: Altered hemostasis in pulmonary hypertension. Blood Coagulation & Fibrinolysis 9:107-17, 1998.
37. Herve P, Launay JM, Scrobohaci ML, Brenot F, Simmoneau G, Petitpretz P, Poubeau P, Cerrina J, Duroux P, Drouet L: Increased plasma serotonin in primary pulmonary hypertension. American Journal of Medicine 99:249-54, 1995.
38. Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J, Hamm M, Fabel H: long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. New England Journal of Medicine 342:1866-70, 2000.
39. Hoeper MM, Sosada M, Fabel H: Plasma coagulation profiles in patients with severe primary pulmonary hypertension. European Respiratory Journal 12:1446-9, 1998.
40. Kawut S, F. S, Ferrari V, DeNofrio D, Axel L, Loh E, Palevsky HI:Extrinsic compression of the left main coronary artery by the pulmonary artery in patients with long-standing pulmonary hypertension. American Journal of Cardiology 83:984-6, 1999.
41. Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM: Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. American Journal of Respiratory and Critical Care Medicine 167:580-583, 2002.
42. Kuo PC, Johnson LB, Plotkin JS, Howell CD, Bartlett ST, Rubin LJ: Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 63:604-16, 1997.
43. Langleben D, Dupuis J, Hirsch A, Giovinazzo M, Langleben I, Khoury J, Ruel N, Caron A: Pulmonary endothelin-1 clearance in human pulmonary arterial hypertension. Chest 128:622S, 2005.
44. Machado RD, James V, Southwood M, Harrison RE, Atkinson C, Stewart S, Morrell NW, Trembath RC, Aldred MA: Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension. Circulation 111:607-613, 2005.
45. McGoon MD, Fuster V, Freeman WK, Edwards WD, Scott JP: The heart and the lungs:pulmonary hypertension. In Mayo Clinic Practice of Cardiology. Edited by ER Guiliani, BJ Gersh, MD McGoon, DL Hayes and HV Schaff, 3rd edition. New York, Mosby Yearbook, 1996, pp 1815-36.
46. McLaughlin V, Sitbon O, Badesch DB, Barst RJ, Black C, Gailie N, Rainisio M, Simonneau G, Rubin L: Survival with firST-line bosentan in patients with primary pulmonary hypertension. European Respiratory Journal 25:244-249, 2005.
47. McLaughlin VV, Genthner DE, Panella MM, Hess DM, Rich S: Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: A case series. Annals of Internal Medicine 130:740-3, 1999.
48. McLaughlin VV, Shillington A, Rich S: Survival in primary pulmonary hypertension: The impact of epoprostenol therapy. Circulation 106:1477-82, 2002.
49. McQuillan BM, Picard MH, Leavitt M, Weymann AE: Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 104:2797-2802, 2001.
50. Mesquita S, Castro C, Ikari N, Oliveira S, Lopes A: Likelihood of left main coronary artery compression based on pulmonary trunk diameter in patients with pulmonary hypertension. American Journal of Medicine 116:369-374, 2004.
51. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W: Inhaled iloprost for severe pulmonary hypertension. New England Journal of Medicine 347:322-9, 2002.
52. Reichenberger F, Popke-Zaba J, McNeil K, Parameshwar J, Shapiro LM: Atrial septostomy in the treatment of severe pulmonary arterial hypertension. Thorax 58:797-800, 2003.
53. Rich S, Brundage BH: high-dose calcium channel-blocking therapy for primary pulmonary hypertension:evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 76:135-41, 1987.
54. Rich S, D'Alonzo GE, Dantzker DR, Levy PS: Magnitude and implications of spontaneous hemodynamic variability in primary pulmonary hypertension. American Journal of Cardiology 55:159-63, 1985.
55. Rich S, Kaufmann E, Levy PS: The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327:76-81, 1992.
56. Rich S, McLaughlin VV, O'Neill W: Stenting ito reverse left ventricular ischemia due to left main coronary artery compression in primary pulmonary hypertension. Chest 120:1412-5, 2001.
57. Rich S, McLaughlin VV: The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. Journal of the American College of Cardiology 34:1184-7, 1999.
58. Rosenzweig EB, Kerstein D, Barst RJ: long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 99:1858-65, 1999.
59. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G: Bosentan therapy for pulmonary arterial hypertension. New England Journal of Medicine 346:896-903, 2002.
60. Sandoval J, Gaspar J, Pulido T, Bautista E, Martinez-Guerra ML, Zeballos M, Palomar A, Gomez A: Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. Journal of the American College of Cardiology 32:297-304, 1998.
61. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine 165:800-4, 2002.
62. Simonneau G, Galie N, Rubin L, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A: Clinical classification of pulmonary hypertension. Journal of American College of Cardiology 43, Supplement 1:S5-S12, 2004.
63. Sitbon O, Humbert M, Jais X, Ioos V, Hamid A, Provencher S, Garcia G, Parent F, Herve P, Simonneau G: long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111:3105-3111, 2005.
64. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, Rainisio M, Simonneau G: longterm intravenous epoprostenol infusion in primary pulmonary hypertension:prognostic factors and survival. Journal of the American College of Cardiology 40:780-8, 2002.
65. Trembath R, Thomson J, Machado R, Morgan NV, Atkinson C, Winship I, Simonneau G, Galie N, Loyd JE, Humbert M, Nichols WC, Morrell N: Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. New England Journal of Medicine 345:325-34, 2001.
66. Weir EK, Reeve HL, Huang JM, Michelakis E, Nelson DP, Hampl V, Archer SL: Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction. Circulation 94:2216-20, 1996.
67. Welsh C, Hassell KL, Badesch DB: Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 110:710-7, 1996.
68. Yuan JJ, Aldinger AM, Juhaszova M, Wang JK, Conte JV, Gaine SP, Orens JB, Rubin LJ: Dysfunctional voltage-gated K + channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 98:1400-6, 1998.